Impact of Genetic Abnormalities on the Prognoses and Clinical Parameters of Patients with Multiple Myeloma
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: We reviewed patients with multiple myeloma (MM) in order to assess the incidence of genetic abnormalities and their associations with clinical parameters, risk groups, and prognosis. Methods: A total of 130 patients with MM were enrolled. The incidences of genetic abnormalities were determined in all patients. The relationships of the genetic abnormalities and clinical parameters were investigated. In addition, a survival analysis was performed. Results: Abnormal karyotypes were detected in 42.3% (N=55) of the patients, and this was increased to 63.1% (N=82) after including the results determined with interphase FISH. Hypodiploidy was observed in 7.7% (N=10) of the patients, and all were included in the group with complex karyotypes (30.8%, N=40). The 14q32 rearrangements were detected in 29.2% (N=38) of the patients, and these most commonly included t(11;14),which was followed by t(4;14) and t(14;16) (16.2%, 11.5%, and 0.8%, respectively). Abnormal karyotypes and complex karyotypes were associated with disease progression markers, including low hemoglobin levels, low platelet counts, high plasma cell burden,high β2-microglobulin, and high international staging system stages. A high free light chain (FLC) ratio and FLC difference were associated with abnormal karyotypes, complex karyotypes, and higher plasma cell burden. Hypodiploidy and low platelet counts were significant independent prognostic factors and were more important in patient outcome than any single abnormality. Conclusions: Genetic abnormalities were associated with disease progression markers and prognosis of MM patients.
Abstract
Background: We reviewed patients with multiple myeloma (MM) in order to assess the incidence of genetic abnormalities and their associations with clinical parameters, risk groups, and prognosis. Methods: A total of 130 patients with MM were enrolled. The incidences of genetic abnormalities were determined in all patients. The relationships of the genetic abnormalities and clinical parameters were investigated. In addition, a survival analysis was performed. Results: Abnormal karyotypes were detected in 42.3% (N=55) of the patients, and this was increased to 63.1% (N=82) after including the results determined with interphase FISH. Hypodiploidy was observed in 7.7% (N=10) of the patients, and all were included in the group with complex karyotypes (30.8%, N=40). The 14q32 rearrangements were detected in 29.2% (N=38) of the patients, and these most commonly included t(11;14),which was followed by t(4;14) and t(14;16) (16.2%, 11.5%, and 0.8%, respectively). Abnormal karyotypes and complex karyotypes were associated with disease progression markers, including low hemoglobin levels, low platelet counts, high plasma cell burden,high β2-microglobulin, and high international staging system stages. A high free light chain (FLC) ratio and FLC difference were associated with abnormal karyotypes, complex karyotypes, and higher plasma cell burden. Hypodiploidy and low platelet counts were significant independent prognostic factors and were more important in patient outcome than any single abnormality. Conclusions: Genetic abnormalities were associated with disease progression markers and prognosis of MM patients.
참고문헌 (29)
- Boyd KD, "A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial", Leukemia, 26, pp.349~355 (2012)
- Kumar SK, "Improved survival in multiple myeloma and the impact of novel therapies", Blood, 111, pp.2516~2520 (2008)
- Avet-Loiseau H, "Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome", Blood, 109, pp.3489~3495 (2007)
- Greipp PR, "International staging system for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)
- Wuilleme S, "Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma", Leukemia, 19, pp.275~278 (2005)
- Cremer FW, "Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics", Genes Chromosomes Cancer, 44, pp.194~203 (2005)
- Fonseca R, "International Myeloma Working Group molecular classification of multiple myeloma: spotlight review", Leukemia, 23, pp.2210~2221 (2009)
- Drach J, "Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization", Cancer Res, 55, pp.3854~3859 (1995)
- Avet-Loiseau H, "Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed but correlate with natural history, immunological features and clinical presentation", Blood, 99, pp.2185~2191 (2002)
- Min CK, "Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone", Jpn J Clin Oncol, 37, pp.961~968 (2007)
- Shaffer LG, "ISCN 2009: an international system for human cytogenetic nomenclature" (2009), Karger
- Ross FM, "Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders", Haematologica, 97, pp.1272~1277 (2012)
- Kumar S, "Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma", Leukemia, 24, pp.1498~1505 (2010)
- Rajkumar SV, "Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management", Am J Hematol, 87, pp.78~88 (2012)
- Kröger N, "Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation", Blood, 103, pp.4056~4061 (2004)
- Christensen JH, "Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark", Cancer Genet Cytogenet, 174, pp.88~99 (2007)
- Dewald GW, "Relationship of patient survival and chromosome anomalies detected in metaphase and", or interphase cells at diagnosis of myeloma, 2005, pp.106, 3553~3558
- Schmidt-Wolf IG, "Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance", Cancer Genet Cytogenet, 167, pp.20~25 (2006)
- Ross FM, "Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma", Leukemia, 19, pp.1634~1642 (2005)
- Kumar S, "Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics", Blood, 119, pp.2100~2105 (2012)
- Kapoor P, "Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie", Mayo Clin Proc, 85, pp.532~537 (2010)
- Fonseca R, "Genetics and cytogenetics of multiple myeloma: a workshop report", Cancer Res, 64, pp.1546~1558 (2004)
- Kumar SK, "Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines", Mayo Clin Proc, 84, pp.1095~1110 (2009)
- Kapoor P, "Update on risk stratification and treatment of newly diagnosed multiple myeloma", Int J Hematol, 94, pp.310~320 (2011)
- Avet-Loiseau H, "Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants", Blood, 101, pp.1570~1571 (2003)
- Stewart AK, "A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy", Leukemia, 21, pp.529~534 (2007)
- Butler C, "Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients", Leuk Lymphoma, 53, pp.2444~2448 (2012)
- San Miguel JF, "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma", N Engl J Med, 359, pp.906~917 (2008)
- Rajkumar SV, "Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management", Am J Hematol, 86, pp.57~65 (2011)